OUD: Cognitive Function and Pain Threshold in People Who Are Methadone Maintained

Sponsor
Yale University (Other)
Overall Status
Completed
CT.gov ID
NCT04027166
Collaborator
(none)
27
1
2
21.9
1.2

Study Details

Study Description

Brief Summary

Male and female participants, over the age of 18, with OUD currently receiving methadone will be enrolled. This within-subject study design will assess pain and cognitive performance in individuals with OUD engaged in MMT. Participants will be asked to complete two separate 4-hour sessions that will be spaced approximately 2-15 days apart. The two sessions will differ based on methadone administration to evaluate study variables in methadone peak (immediately after dose) and trough (20-24 hour after last dose) states. The order of these sessions will be counterbalanced across participants. At the beginning of each session, participants will complete a pain sensitivity task at baseline and post-methadone administration to determine pain threshold and tolerance. Participants will then complete computerized cognitive assessments of working memory, set-shifting, attentional bias, and behavioral inhibition. The cognitive assessments will administered across three time-points (0, 90, and 180 minutes). Pain threshold and tolerance will be measured again after 240 minutes. In addition, opioid craving, withdrawal, pain intensity, and emotional valence will be repeatedly assessed during 240 minute session.

Condition or Disease Intervention/Treatment Phase
Early Phase 1

Detailed Description

After completion of the phone screen, eligible participants will be brought into the laboratory, given a description of the study, and assessed on inclusion and exclusion criteria by research personnel. Details pertaining to the cognitive measures, pain measures, and methadone manipulation will be discussed and informed consent will be obtained along with a signed release to allow study personnel to monitor opioid maintenance. Information on medical, psychiatric and drug use histories will be collected. Individuals with a history of vascular problems or high blood pressure will be evaluated by the research physician. In addition, laboratory tests collecting information on blood alcohol content and urine toxicology will be conducted. Participants will be deemed ineligible to participate if they are not medically cleared by research clinician. Veterans who have a positive BAC will be rescheduled and the methadone maintenance program's clinical protocol will be implemented.

All sessions will be conducted at the West Haven VA Connecticut Healthcare Campus. Participants will be asked to complete two sessions, approximately 2-15 days apart. Order of peak and trough sessions will be counterbalanced between participants. Each session will last approximately four hours. Prior to each testing session, participants will be asked to refrain from caffeine for at least one hour. They will be served a standardized breakfast (i.e., bagel and cream cheese) and offered one smoke break prior to beginning the experimental session. They will be asked to refrain from smoking until the completion of the study protocol. Methadone administration will be coordinated with methadone maintenance treatment staff to relay information about which condition the participant will complete on a given session. At the start of each session, participants will complete computerized cognitive assessments and self-report questionnaires. The computerized cognitive measures will repeated at hours 0, 1.5, and 3. Several state questionnaires will be administered at hours every 30 minutes. Participants will also complete a pain sensitivity measure (i.e., cold pressor task) to assess baseline threshold and tolerance at hour 0 and hour 4.

This study is complete with 27 enrolled and 20 completers.

Study Design

Study Type:
Interventional
Actual Enrollment :
27 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Intervention Model Description:
This within-subject study design will assess pain and cognitive performance in individuals with OUD engaged in MMT. Participants will be asked to complete two separate 4 hours sessions that will be spaced approximately 2-15 days apart. The two sessions will differ based on methadone administration to evaluate study variables in methadone peak (immediately after dose) and trough (20-24 hour after last dose) states.This within-subject study design will assess pain and cognitive performance in individuals with OUD engaged in MMT. Participants will be asked to complete two separate 4 hours sessions that will be spaced approximately 2-15 days apart. The two sessions will differ based on methadone administration to evaluate study variables in methadone peak (immediately after dose) and trough (20-24 hour after last dose) states.
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
Effects of Methadone on Cognitive Function and Pain Threshold
Actual Study Start Date :
Jul 1, 2019
Actual Primary Completion Date :
Mar 10, 2021
Actual Study Completion Date :
Apr 28, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: administration immediate

Methadone will be administered prior to study procedures

Drug: Methadone
Methadone will be administered before study procedures

Experimental: administration delayed

Methadone will be held for four hours until the end of all study procedures.

Drug: Methadone
Methadone will be delayed (4 hours) until the end of the procedures

Outcome Measures

Primary Outcome Measures

  1. changes in cognitive functioning using the go no go task [up to 24 months]

    during methadone peak and trough states.

Secondary Outcome Measures

  1. self-reported measures of pain from the cold pressor test [up to 24 months]

    during methadone peak and trough states

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Males and females, over the age of 18

  • Diagnosed with opioid dependence and currently enrolled in methadone maintenance treatment

  • Compliant in opioid maintenance treatment and on a stable dose for two weeks or greater

  • No current medical problems deemed contraindicated for participation by physician investigator

Exclusion Criteria:
  • History of psychosis as determined by review of EMR.

  • Acute suicidal ideation.

  • History of medical conditions that the physician investigator deems contraindicated for inclusion in the study (e.g., untreated hypertension)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Veteran Affairs Hospital West Haven Connecticut United States 06516

Sponsors and Collaborators

  • Yale University

Investigators

  • Principal Investigator: Mehmet Sofuoglu, M.D., Ph.D., Veteran Affairs Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Mehmet Sofuoglu, Principal Investigator, Yale University
ClinicalTrials.gov Identifier:
NCT04027166
Other Study ID Numbers:
  • MS057
First Posted:
Jul 19, 2019
Last Update Posted:
Jul 20, 2021
Last Verified:
Jul 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 20, 2021